Project description
A medical device for real-time analysis during tumour surgery
Surgical resection of tumours requires pre-operative planning, while the outcome is assessed through pathological examination after the operation. The rationale behind the EU-funded Olfactomics project is that real-time analysis of the operated tissue is necessary for optimal results. Researchers have developed a breakthrough medical device that assists surgeons in effectively resecting the tumour tissue, sparing the neighbouring normal tissue. The device does not compromise the workflow of the operation and can be employed for most soft-tissue surgeries, reducing the need for reoperation. Considering the number of tumour surgeries performed every year, there is a big market niche for the Olfactomics device.
Objective
Olfactomics is a Finnish university-based spinoff company developing a novel technology for surgical tissue assessment. The company has a breakthrough innovation on improving breast-conserving lumpectomies where a residual tumour continues to be an issue. Real-time tissue analysis allows the surgeon to remove a whole tumour in one operation and minimise the resection of healthy tissues. The patented technology (TRL 6) allows safer and more cost-effective cancer surgery and is scalable to most soft-tissue surgery. The unique device allows the surgeon to analyse the operated tissue in real-time during cancer surgery leading to optimal tissue removal.
There is a global economy-justified need for real-time analysis in surgery. The Olfactomics device is fully aligned with current clinical workflow and instrumentation. It can be efficiently implemented to 835 000 breast surgeries every year, and it is scalable to multiple other areas. The commercialisation is targeting to 250 M€ revenue by 2027.
The core team has the enthusiasm and knowledge needed for the commercialisation: team members are specialists in surgery, clinical medicine, medical technology, software, data analysis, financial sector and corporate law and have excellent connections in the international healthcare industry.
The aim of this feasibility study is to analyse the feasibility from different perspectives and detail the business plan for the global commercialisation of the technology. The first commercial product will be a research device launched 2019. The scale-up to medical device and applications on several surgical areas will follow.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicinesurgerysurgical specialties
- medical and health sciencesclinical medicineoncologybreast cancer
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
33700 Tampere
Finland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.